U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07215806) titled 'Effect of Evobrutinib on Pharmacokinetics of a Combined Oral Contraceptive' on Oct. 08.
Brief Summary: The purpose of this study was to assess the effect of M2951 on the pharmacokinetics (PK) of a combined oral contraceptive [Ethinyl estradiol/Norethisterone (EE/NET)] in healthy female participants.
* Study Duration: up to 46 days
* Treatment Duration: Days 4 to 17 (14 days treatment with M2951); Days 1 and 15 (2 days treatment with Combined Oral Contraceptive [COC])
* Visit Frequency: Participants were resident in the Clinical Research Unit from Day -1 to Day 18.
Study Start Date: Aug. 24, 2022
Study Type: INTERVENTIONAL
Cond...